Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

NCT06409429 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Nimotuzumab
DRUG: GX
DRUG: Placebo

Sponsor

Tianjin Medical University Cancer Institute and Hospital